ArticleBritish journal of haematology2026
Deacetylase inhibitors CM-444 and CM-1758 enhance chemotherapy response in AML via ALOX5.
Naroa Gimenez-Camino, Edurne San José-Enériz, Leire Garate, Estibaliz Miranda, Elena Sáez, Antonio Pineda-Lucena, Felipe Prósper, Xabier Agirre
Abstract read
In one paragraphArticle in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Naroa Gimenez-CaminoCenter for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Edurne San José-EnérizCenter for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Leire GarateCancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain.
Estibaliz MirandaCenter for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Elena SáezCenter for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Antonio Pineda-LucenaCenter for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Felipe PrósperCenter for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Xabier AgirreCenter for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Funding
Departamento de Salud, Gobierno de Navarra GN2023/11Departamento de Salud, Gobierno de Navarra GNS_44-2021Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra 0011-1411-2022-000068Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra 0011-1411-2022-000077Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra NANO-ProtacsInstituto de Salud Carlos III CIBERONC (CB16/12/00489)Instituto de Salud Carlos III ERANET TRANSCAN-3 JTC 2024 (TOSCANINI)Instituto de Salud Carlos III PI023/516Instituto de Salud Carlos III PI22/00947Instituto de Salud Carlos III PI23/00488Instituto de Salud Carlos III PMP22/00069
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
acute myeloid leukaemiaALOX5chemosensitizationepigenetic therapyHDAC inhibitors
Identifiers
PMID42052754
PMCPMC13340537
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390